Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

@article{Bryant2005SpecificKO,
  title={Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase},
  author={Helen E. Bryant and Niklas Schultz and Huw D. Thomas and Kayan M. Parker and Dan Flower and Elena Lopez and Suzanne Kyle and Mark Meuth and Nicola J. Curtin and Thomas Helleday},
  journal={Nature},
  year={2005},
  volume={434},
  pages={913-917}
}
Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient… Expand

Paper Mentions

Interventional Clinical Trial
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs… Expand
ConditionsAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
InterventionDrug
Expanded Access Clinical Trial
This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are… Expand
ConditionsMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
InterventionDrug
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
TLDR
While BRCA1-depleted or -mutated cells were hypersensitive to the clinically approved PARPi olaparib, its toxicity was significantly attenuated by treatment with reactive oxygen species scavengers, growth under hypoxic conditions or chemical OGG1 inhibition. Expand
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
TLDR
It is reported that PARP inhibitor-resistant BRCA2-mutant cells revert back to normal levels of PARP activity, and it is speculated that the reason for the sensitivity of HR-defective cells to PARP inhibitors is related to the hyperactivated PARP1 in these cells. Expand
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency
TLDR
It is shown that CAPAN-1 cells are in fact very sensitive to the potent PARP inhibitors KU0058684 (IC50 3.2nM) and K U0058948 (IC 50 3.4nM), and treatment with potent ParP inhibitors remains an exciting potential therapy for cancers involving BRCA1 or BRCa2 deficiency. Expand
Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells
TLDR
It is shown that loss of the MLL3/4 complex protein, PTIP, protects Brca1/2- deficient cells from DNA damage and rescues the lethality of Brca2-deficient embryonic stem cells, but PTIP deficiency does not restore homologous recombination activity at double-strand breaks. Expand
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
TLDR
Because biologically active doses of PARP inhibitors caused minimal toxicity in phase I to II clinical trials, careful scheduling of these agents in combination with radiotherapy may maintain the therapeutic ratio and increase tumor radiocurability. Expand
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
TLDR
Evidence regarding various explanations for the ability of PARP inhibitors to selectively kill HR-deficient cancer cells is reviewed and their potential implications are discussed. Expand
Identification of regulators of poly-ADP-ribose polymerase (PARP) inhibitor response through complementary CRISPR knockout and activation screens
TLDR
This work provides a comprehensive set of putative biomarkers that serve to better understand and predict PARPi response, and identifies a novel pathway of PARPi resistance in BRCA2-deficient cells. Expand
Poly(ADP-ribose) Polymerase (PARP-1) in Homologous Recombination and as a Target for Cancer Therapy
TLDR
Although PARP-1 appears not to be required for homologous recombination itself, it regulates the process through its involvement in the repair of DNA single-strand breaks (SSBs), which triggers homological recombination for replication restart. Expand
Molecular Pathways: Targeting PARP in Cancer Treatment
TLDR
It is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting. Expand
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
TLDR
It is concluded that ALC1-dependent PARP1 mobilization is a key step underlying PARP inhibitor resistance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
TLDR
Data indicate that PARP-1 is dispensable in HR induced by DSBs, but is involved in the repair and reactivation of stalled replication forks. Expand
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
TLDR
The data suggest that PARP-1 controls DNA damage recognised by HR and that it is not involved in executing HR as such. Expand
PARP is important for genomic stability but dispensable in apoptosis.
TLDR
Although PARP is specifically cleaved during apoptosis, cells lacking this molecule apoptosed normally in response to treatment with anti-Fas, tumor neurosis factor alpha, gamma-irradiation, and dexamethasone, indicating thatPARP is dispensable in apoptosis and that PARP-/- thymocytes are not hypersensitive to ionizing radiation. Expand
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
TLDR
BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage. Expand
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.
TLDR
Results demonstrate that PARP is a survival factor playing an essential and positive role during DNA damage recovery, and inactivated both alleles by gene targeting in mice. Expand
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.
TLDR
The data demonstrate that PARP-1 is required for the assembly or stability of XRCC1 nuclear foci after oxidative DNA damage and suggest that the formation of these foci is mediated via interaction with poly (ADP-ribose). Expand
Loss of poly(ADP‐ribose) polymerase‐1 causes increased tumour latency in p53‐deficient mice
TLDR
The generation of doubly null mutant mice was reported and it was found that tumour‐free survival of parp‐1‐/−p53−/− mice increased by 50% and iNOS expression and nitrite release were dramatically reduced in the parp-1‐1−/+p53-/−− mice compared with par p‐1+/+p53‐/+ mice. Expand
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
TLDR
AG14361 is, to the authors' knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer. Expand
Brca2 (XRCC11) Deficiency Results in Radioresistant DNA Synthesis and a Higher Frequency of Spontaneous Deletions
TLDR
It is shown that the radiosensitive Chinese hamster cell mutant (V-C8) of group XRCC11 is defective in the breast cancer susceptibility gene Brca2, which causes hypersensitivity to various DNA-damaging agents with an extreme sensitivity toward interstrand DNA cross-linking agents. Expand
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
TLDR
It would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage, and PARP inhibitors may be potentially useful in combination with topoisomerase I inhibitor anticancer chemotherapy. Expand
...
1
2
3
...